Abstract
Background
Sarcopenia research may be hampered by the heterogeneity of populations and outcome measures used in clinical studies.
Aim
The aim of this study was to describe the inclusion/exclusion criteria and outcome measures used in ongoing research in sarcopenia.
Methods
All active intervention studies registered in the World Health Organization with the keyword sarcopenia were included. Study design, type of intervention, inclusion/exclusion criteria and outcome measures were registered and classified.
Results
In April 2014, 151 studies on sarcopenia were registered in the WHO database. One hundred twenty-three were intervention studies. Most trials (94.3 %) were single centre and randomized (93.5 %), 51.2 % were double blind. Nutritional interventions (36.6 %), physical exercise (12.2 %) or both (19.5 %) were the most common interventions tested. Only 54.4 % included subjects of both genders, and 46.3 % had an upper age limit. Definition of the target populations was heterogeneous, with 57.7 % including healthy subjects and none using recent definitions of sarcopenia. Lifestyle and the degree of physical activity of subjects were not described or considered in most cases (79.7 %). Subjects with cardiovascular, neuropsychiatric or metabolic disorders and those with physical disability were usually excluded. Muscle mass and muscle strength were the primary outcome variables in 28.5 and 29.5 % of studies and physical performance in 19.5 %, but only 4.1 % used the three variables used the three of them. An additional 26.8 % used biological outcome variables. Little information and agreement existed in the way muscle and physical performance parameters were measured.
Conclusions
We found a large heterogeneity in trial design, definition of populations and outcome measures in present research.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39(4):412–423
Cruz-Jentoft AJ, Triana FC, Gómez-Cabrera MC et al (2011) The emergent role of sarcopenia: Preliminary Report of the Observatory of Sarcopenia of the Spanish Society of Geriatrics and Gerontology. Rev Esp Geriatr Gerontol 46(2):100–110
Cruz-Jentoft AJ, Landi F, Schneider SM et al (2014) Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 43(6):748–759
Patel HP, Syddall HE, Jameson K et al (2013) Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: finding from the Hertfordshire Cohort Study (HCS). Age Ageing 42(3):378–384
Studenski S (2009) What are the outcomes of treatment among patients with sarcopenia? J Nutr Health Aging 13(8):733–736
Chumlea WC, Cesari M, Evans WJ et al (2011) Sarcopenia: designing phase IIB trials. J Nutr Health Aging 15(6):450–455
Rubbieri G, Mossello E, Di Bari M (2014) Techniques for the diagnosis of sarcopenia. Clin Cases Miner Bone Metab 11(3):181–184
Beaudart C, Reginster JY, Slomian J et al (2014) Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. J Musculoskelet Neuronal Interact 14(4):425–431
Cooper C, Fielding R, Visser M et al (2013) Tools in the assessment of sarcopenia. Calcif Tissue Int 93(3):201–210
Dam TT, Peters KW, Fragala M et al (2014) An evidence-based comparison of operational criteria for the presence of sarcopenia. J Gerontol A Biol Sci Med Sci 69(5):584–590
Studenski SA, Peters KW, Alley DE et al (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 69(5):547–558
Vellas B, Pahor M, Manini T, Rooks D, Guralnik JM, Morley J et al (2013) Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations. J Nutr Health Aging 17(7):612–618
Reginster JY, Cooper C, Rizzoli R et al (2016) Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clin Exp Res 28(1):47–58
Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquín B et al (2013) Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc 61(5):734–738
Dodds R, Sayer AA (2014) Sarcopenia. Arq Bras Endocrinol Metabol 58(5):464–469
Lynch GS (2008) Update on emerging drugs for sarcopenia—age-related muscle wasting. Expert Opin Emerg Drugs 13(4):655–673
Tieland M, van de Rest O, Dirks ML et al (2012) Protein supplementation improves physical performance in frayl elderly people: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc 13(8):720–726
Barbat-Artigas S, Plouffe S, Pion CH et al (2013) Toward a sex-specific relationship between muscle strength and appendicular lean body mass index? J Cachexia Sarcopenia Muscle 4(2):137–144
Cruz-Jentoft AJ, Gutiérrez B (2010) Upper age limits in studies submitted to a research ethics committee. Aging Clin Exp Res 22(2):175–178
Cherubini A, Del Signore S, Ouslander J et al (2010) Fighting against age discrimination in clinical trials. J Am Geriatr Soc 58(9):1791–1796
Pahor M, Guralnik JM, Ambrosius WT et al (2014) Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA 311(23):2387–2396
Cawthon PM, Peters KW, Shardell MD et al (2014) Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci 69(5):567–575
Cherubini A, Oristrell J, Pla X et al (2011) The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 171(6):550–556
Filippin LI, Teixeira VN, da Silva MP et al (2015) Sarcopenia: a predictor of mortality and the need for early diagnosis and intervention. Aging Clin Exp Res. 27(3):249–254
Acknowledgments
Gloria Peña has received research grants from Consejo Nacional de Ciencia y Tecnología (CONACYT). Alfonso J. Cruz-Jentoft declares that he has taken part in clinical trials on sarcopenia sponsored by Abbott Nutrition, Novartis and Regeneron. He has also received speaker or consultancy honoraria from Abbott Nutrition, Nestlé, Nutricia and Regeneron.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Lilia Patricia Bustamante, Ninfa Ramirez Duran and Carmen Sánchez declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
For this type of study informed consent is not required.
Rights and permissions
About this article
Cite this article
Peña Ordóñez, G.G., Bustamante Montes, L.P., Ramírez Duran, N. et al. Populations and outcome measures used in ongoing research in sarcopenia. Aging Clin Exp Res 29, 695–700 (2017). https://doi.org/10.1007/s40520-016-0610-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40520-016-0610-x